BioAge Labs, Inc. (BIOA)
| Market Cap | 448.55M |
| Revenue (ttm) | 5.92M |
| Net Income (ttm) | -75.79M |
| Shares Out | 35.86M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,876 |
| Open | 12.29 |
| Previous Close | 12.46 |
| Day's Range | 12.00 - 12.74 |
| 52-Week Range | 2.88 - 13.10 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.33 (-9.43%) |
| Earnings Date | Nov 6, 2025 |
About BIOA
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BIOA stock is "Buy." The 12-month stock price target is $11.33, which is a decrease of -9.43% from the latest price.
News
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area.
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cy...
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
The weight-loss drug market is already enormous, but could nearly double in size by 2035. BioAge Labs is still years away from revenue and even more years away from actual profits.
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs.
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetites.
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to ac...
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m...
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of propr...
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform ...
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases,...
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships wit...
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
LOS ANGELES , March 10, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the f...
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
NEW YORK , March 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the regi...
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman
BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman
BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline SAN FRANCISCO, CA / ACCESS Newswire / March 6, 2025 / BioAge Labs, Inc. (NASDAQ:BIOA) is abandoning developmen...
BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
NEW YORK , March 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the regist...
BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman
BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline
BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)
NEW YORK, March 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its ...
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
BIOA Investors with Losses Encouraged to Contact the Firm Before Mar. 10th, 2025 Deadline SAN FRANCISCO, CA / ACCESS Newswire / March 1, 2025 / BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning developme...
BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
NEW YORK , Feb. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the regist...